Date: Feb 8, 2016
Location: Cambridge, MA, US
Company: Biogen
| External Posting Title | Intern: Clinical Development, Hemophilia Hematology Development |
| Job Description | This is a full-time Internship role from June-August 2016. Biogen rare disease early development is a newly created function within the Biogen R&D organization. We currently are focusing on non-malignant hematology, ophthalmology and neurology utilizing therapeutic modalities from small molecules, proteins, oligonucleotides, to cell and gene therapies to address significant unmet needs for many adult and pediatric patients afflicted by numerous rare/orphan diseases. Examples of some of our currently ongoing programs include: - The Biogen/Sangamo clinical development program utilizes the zinc finger folk nuclease technology to ex-vivo edit the autologous CD34 hematopoietic stem cell BCL11a enhancer in an attempt to up-regulate the HbF expression and to cure beta thalassemia and sickle cell disease. - The Biogen/AGTC clinical development program utilizes the AAV2 viral vector to deliver genes to correct inherited monogenic blindness including X-Linked Retinoschisis and X-Linked Retinitis Pigmentosa. - The Biogen/TIGET clinical development program utilizes lentiviral vectors to deliver clotting factors VIII and IX genes to treat hemophilia A and B A qualified intern will benefit from exposures to the latest advancement and challenges in gene therapies, the dynamic early development environment, strategic discussions of internal pipeline and external assets, and will craft his/her own goals and job descriptions. |
| Location | Cambridge, MA, US |
| Job Category | Internship |
| Requisition Number | 27443BR |
No comments:
Post a Comment